Pancreatitis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook
2020 Pancreatitis PIPELINE HIGHLIGHTS
Pancreatitis is one of the widely researched conditions during 2020 with 23 companies actively focusing on realizing pipeline’s potential. Development of Pancreatitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Pancreatitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Pancreatitis.
Good progress is anticipated during 2020 and 2021 with Pancreatitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Pancreatitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Pancreatitis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Pancreatitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Pancreatitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Pancreatitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Pancreatitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Pancreatitis DRUG PROFILES
Pancreatitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
Both small size and large size pharmaceutical companies are investing their resources in Pancreatitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Pancreatitis. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 23 Pancreatitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Pancreatitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Angion Biomedica Corp, AzurRx BioPharma Inc, Baylor Scott & White Health, Bessor Pharma LLC , Bharat Serums And Vaccines Ltd, BioNTech SE, CalciMedica Inc, Centeer BioTherapeutics, Cypralis Ltd, Daewoong Pharmaceutical Co Ltd, Generon (Shanghai) Corp, GlaxoSmithKline , GNT Pharma Co Ltd, LipimetiX Development, MallInckrodt, Novartis AG, PNB Vesper Life Science Pvt Ltd, SCM lifescience Co Ltd, Shenzhen HighTide Biopharmaceutical Ltd, SN BioScience, Sun BioPharma, Takeda Pharmaceutical, Theraly Fibrosis Inc
REASONS TO BUY
Pancreatitis is one of the widely researched conditions during 2020 with 23 companies actively focusing on realizing pipeline’s potential. Development of Pancreatitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Pancreatitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Pancreatitis.
Good progress is anticipated during 2020 and 2021 with Pancreatitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Pancreatitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Pancreatitis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Pancreatitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Pancreatitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Pancreatitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Pancreatitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Pancreatitis DRUG PROFILES
Pancreatitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
- Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
- Phase of development
- Mechanism of Action
- Route of Administration
- Companies involved including originator, licensing companies, developer, investors, and others
- New molecular entity details
- Orphan drug designation and other special status provided by regulators
Both small size and large size pharmaceutical companies are investing their resources in Pancreatitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Pancreatitis. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 23 Pancreatitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Pancreatitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Angion Biomedica Corp, AzurRx BioPharma Inc, Baylor Scott & White Health, Bessor Pharma LLC , Bharat Serums And Vaccines Ltd, BioNTech SE, CalciMedica Inc, Centeer BioTherapeutics, Cypralis Ltd, Daewoong Pharmaceutical Co Ltd, Generon (Shanghai) Corp, GlaxoSmithKline , GNT Pharma Co Ltd, LipimetiX Development, MallInckrodt, Novartis AG, PNB Vesper Life Science Pvt Ltd, SCM lifescience Co Ltd, Shenzhen HighTide Biopharmaceutical Ltd, SN BioScience, Sun BioPharma, Takeda Pharmaceutical, Theraly Fibrosis Inc
REASONS TO BUY
- The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
- This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
- Buyers can identify most promising drug candidates for treatment of Pancreatitis
- It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
- Users can estimate possible delays in the delivery of pipeline or launch of new products
- Stay ahead of competition through understanding their pipeline progression, strategies and outlook
- The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
- Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO PANCREATITIS
1.1 Pancreatitis- Disease overview
1.2 Pancreatitis- Market Size
1.3 Pancreatitis- Companies Involved
2. PANCREATITIS PIPELINE SNAPSHOT- 2020
2.1 Pancreatitis Pipeline by Phase
2.2 Pancreatitis Pipeline by Mechanism of Action
2.3 Pancreatitis Pipeline by Route of Administration
2.4 Pancreatitis Pipeline- New Molecular Entities
2.5 Pancreatitis Pipeline- Orphan Drug Designation/ Special Designation
3. PANCREATITIS DRUG PROFILES
3.1 Current Status
3.2 Pancreatitis Drug Snapshot
3.3 Pancreatitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Angion Biomedica Corp Pancreatitis Pipeline Insights and Clinical Trials
4.2 AzurRx BioPharma Inc Pancreatitis Pipeline Insights and Clinical Trials
4.3 Baylor Scott & White Health Pancreatitis Pipeline Insights and Clinical Trials
4.4 Bessor Pharma LLC Pancreatitis Pipeline Insights and Clinical Trials
4.5 Bharat Serums And Vaccines Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.6 BioNTech SE Pancreatitis Pipeline Insights and Clinical Trials
4.7 CalciMedica Inc Pancreatitis Pipeline Insights and Clinical Trials
4.8 Centeer BioTherapeutics Pancreatitis Pipeline Insights and Clinical Trials
4.9 Cypralis Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.10 Daewoong Pharmaceutical Co Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.11 Generon (Shanghai) Corp Pancreatitis Pipeline Insights and Clinical Trials
4.12 GlaxoSmithKline Pancreatitis Pipeline Insights and Clinical Trials
4.13 GNT Pharma Co Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.14 LipimetiX Development Pancreatitis Pipeline Insights and Clinical Trials
4.15 MallInckrodt Pancreatitis Pipeline Insights and Clinical Trials
4.16 Novartis AG Pancreatitis Pipeline Insights and Clinical Trials
4.17 PNB Vesper Life Science Pvt Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.18 SCM lifescience Co Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.19 Shenzhen HighTide Biopharmaceutical Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.20 SN BioScience Pancreatitis Pipeline Insights and Clinical Trials
4.21 Sun BioPharma Pancreatitis Pipeline Insights and Clinical Trials
4.22 Takeda Pharmaceutical Pancreatitis Pipeline Insights and Clinical Trials
4.23 Theraly Fibrosis Inc Pancreatitis Pipeline Insights and Clinical Trials
5. PANCREATITIS MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
1.1 Pancreatitis- Disease overview
1.2 Pancreatitis- Market Size
1.3 Pancreatitis- Companies Involved
2. PANCREATITIS PIPELINE SNAPSHOT- 2020
2.1 Pancreatitis Pipeline by Phase
2.2 Pancreatitis Pipeline by Mechanism of Action
2.3 Pancreatitis Pipeline by Route of Administration
2.4 Pancreatitis Pipeline- New Molecular Entities
2.5 Pancreatitis Pipeline- Orphan Drug Designation/ Special Designation
3. PANCREATITIS DRUG PROFILES
3.1 Current Status
3.2 Pancreatitis Drug Snapshot
3.3 Pancreatitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Angion Biomedica Corp Pancreatitis Pipeline Insights and Clinical Trials
4.2 AzurRx BioPharma Inc Pancreatitis Pipeline Insights and Clinical Trials
4.3 Baylor Scott & White Health Pancreatitis Pipeline Insights and Clinical Trials
4.4 Bessor Pharma LLC Pancreatitis Pipeline Insights and Clinical Trials
4.5 Bharat Serums And Vaccines Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.6 BioNTech SE Pancreatitis Pipeline Insights and Clinical Trials
4.7 CalciMedica Inc Pancreatitis Pipeline Insights and Clinical Trials
4.8 Centeer BioTherapeutics Pancreatitis Pipeline Insights and Clinical Trials
4.9 Cypralis Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.10 Daewoong Pharmaceutical Co Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.11 Generon (Shanghai) Corp Pancreatitis Pipeline Insights and Clinical Trials
4.12 GlaxoSmithKline Pancreatitis Pipeline Insights and Clinical Trials
4.13 GNT Pharma Co Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.14 LipimetiX Development Pancreatitis Pipeline Insights and Clinical Trials
4.15 MallInckrodt Pancreatitis Pipeline Insights and Clinical Trials
4.16 Novartis AG Pancreatitis Pipeline Insights and Clinical Trials
4.17 PNB Vesper Life Science Pvt Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.18 SCM lifescience Co Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.19 Shenzhen HighTide Biopharmaceutical Ltd Pancreatitis Pipeline Insights and Clinical Trials
4.20 SN BioScience Pancreatitis Pipeline Insights and Clinical Trials
4.21 Sun BioPharma Pancreatitis Pipeline Insights and Clinical Trials
4.22 Takeda Pharmaceutical Pancreatitis Pipeline Insights and Clinical Trials
4.23 Theraly Fibrosis Inc Pancreatitis Pipeline Insights and Clinical Trials
5. PANCREATITIS MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
